expect emerging-market opportun help
 record give us paus
updat forecast estim aug
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research aug
estim aug
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
myriad acquisit divestitur past decad
constant state evolut
firm transform reduc exposur cyclic market
increas focu environment human health offer
nonstop busi shuffl yet produc sustain return
capit invest competit posit
certainli shift better though sever attract
avenu growth reach particularli emerg market firm
could final produc tangibl benefit sharehold
view neonat screen busi crown jewel
product portfolio firm hold lead posit
neonat prenat matern test screen bulk
babi test world-wide market character
stabl profit price power yet main opportun
newborn screen busi lie oversea emerg market
half chines newborn screen
kit major undergo test three four
disord compar disord firm
capit vast potenti market along
india latin america emerging-market opportun also
abound firm infecti diseas product line
environment segment grow emphasi qualiti life
segment posit benefit strong secular
demand emerging-market revenu expect
shift revenu mix toward diagnost area help lessen
exposur low-margin industri end market
offer better growth profil howev futur valu creation
conting greater disciplin firm capital-alloc
strategi -- strongest suit past compani
taken step shed weak asset support attract
diagnost acquisit includ billion euroimmun
purchas remain skeptic enough valu
creation justifi level invest year
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
provid instrument consum servic
pharmaceut biomed chemic environment gener
industri market compani oper two segment diagnost
includ prenat screen infecti diseas test
discoveri analyt solut compos life scienc industri
environment food applic offer product
servic rang genet screen environment analyt tool
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
increas fair valu estim per share
boost revenu forecast reflect
increas expect euroimmun acquisit
along stronger revenu growth
reproduct health infecti diseas oper
emerg market valuat impli adjust
forward price-to-earnings multipl approxim
expect high-single-digit revenu growth perkinelm
driven mostli compani diagnost
newborn
screen remain healthi addit growth
compani euroimmun acquisit add increment
benefit compani diagnost channel forecast
discoveri analyt solut segment post
mid-single-digit organ growth furthermor
chines emerg market demand analyt
instrument bolster firm environment
compani growth margin return invest
capit profil improv sale medic
imag busi anticip improv global
posit optim infrastructur boost
firm adjust oper margin
slightli manag target even
improv oper margin remain
lower end life scienc space averag five-year
return capit hover near model assum
compani weight averag cost capit
stabil gain divers product line
rel stabl end market partial off-set potenti
technolog disrupt emerging-market risk
rang outcom compani start per share
bear case per share optimist bull
scenario one main concern includ firm abil
creat strateg value-enhanc growth emerg
market maintain profit face
persist tough price macroeconom environ
bull-cas scenario low-double-digit revenu growth
driven diagnost segment assum
acceler growth emerging-market region along
solid newborn screen menu expans
adopt shift product mix toward higher-margin life
scienc oper provid posit impact gross
margin signific margin expans would posit
compani close peer conting upon
see possibl value-dilut acquisit
would provid downward pressur valuat
weigh industri academ sale next coupl
year push revenu growth low singl digit
also assum forc accept
price concess order maintain market share
temper environment health sale slightli
break-even level scenario margin expans
materi
believ overal busi possess
econom moat firm competit posit
discoveri analyt solut approxim
perkin busi close euroimmun deal
weaker peer depress outlook
although compani tie higher-end academ
pharmaceut end market space overrun
entrench larger player like agil thermo fisher
bode well current suit
instrument result return invest capit
struggl cover cost past sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
babi rapidli expand newborn popul
emerg market particularli china brazil longer
ramp-up process india may lead slower growth
firm achiev china howev
repres sale approxim
post-euroimmun augment diagnost segment
parent pay annuiti store child stem cell
chanc cell necessari treatment later
life creat stabl revenu sourc
virtual prohibit regulatori barrier privat
bank industri reput paramount stem cell
storag busi parent highli sensit qualiti
servic consid potenti life-sav viacord
wide recogn formid player space
industri statist impli low chanc babi
benefit bank cell continu advanc
stem cell therapi offer potenti capabl
self-bank stem cell futur
even share diagnost revenu increas
segment repres major
addit manag histor
deploy capit bolt-on acquisit mani tuck
no-moat segment littl build firm
competit advantag opinion
view overal moat trend stabl
advantag opinion discoveri analyt
discoveri segment primarili cater industri
commerci user sensit price rather
increment product sophist favor secular
demand kept busi afloat seem
littl stop competitor steal market
share bigger player impress margin like
weak medic imag busi significantli improv
compani foot wed like see consist
posit capit alloc decis award
diagnost busi amount roughli
revenu approxim revenu close
euroimmun deal provid differ stori
well-establish nich newborn screen compani
appli tandem mass spectrometri ms/m
newborn screen market earli thank well-tim
partnership leader mass spectrometri
ms/m standard newborn screen use
measur multipl molecul significantli
reduc test time cost allow analysi
chemic level combin rather isol
intangibles-includ firm extens test menu
technolog expertis
establish relationship govern hospit -- increas
barrier entri
razor-and-blad model newborn screen busi
make custom hesit switch provid
compani test perform major -born
space
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
water agil better equip compet price
technolog capabl
disrupt innov genom sequenc could
also upset compani otherwis solid newborn
screen busi futur howev think
enough time industri
proactiv reposit near term compani
stand benefit growth newborn screen
emerg market number mandat test
util rate expand correspond barrier
entri cheap indigen manufactur larg
multi-national player would consid upgrad
moat trend posit given market share take-over
discoveri analyt segment compani focus
capit expenditur toward diagnost unit
outweigh no-moat part busi
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
well-entrench nich newborn
screen stand benefit grow adopt
menu expans emerg market particularli
odevelop countri face grow pressur
improv air water qualiti
lead provid environment test instrument
well posit profit secular trend
orec initi improv oper
effici dramat expand firm margin
sinc way go
financi statement past
litter numer
decad
myriad
restructur charg result
acquisit disposit
state
acquisit firm keep financi
oth compani profit among lowest
industri larg due sub-optimal oper
oth analyt instrument space extrem
crowd littl stop competitor steal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
carri manag debt load view
histori consist acquisit tend keep
financi leverag elev exampl part
billion euroimmun acquisit manag ad
million debt still believ focal
strategi compani continu expand
presenc diagnost emerg market perkinelm
pay small dividend given indic
will increas pay-out ratio near futur
adjust free
gener
gener revolv adjust
commit
potenti technolog disrupt emerging-market
risk partial off-set stabil gain divers
product line rel stabl end market
investor risk overpay
overprun integr result
struggl gener above-cost return capit
past addit analyt instrument bulk
firm could easili lose share cheaper local
competitor larger intern player act
firm
success adapt strategi futur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
assign perkinelm poor stewardship rate
execut team -- led ceo robert friel sinc
shown pedestrian record far come
valu creation sharehold return compani
deploy free cash oper
increas debt level acquisit yet
produc meaning contribut return
favor strateg shift away cyclic product line
result nonetheless subpar particularli
compar mani peer analyt instrument
admittedli last recess cycl disrupt
strategi compani decad stagnant
oper margin half year
manag bare exceed cost capit includ
goodwil meanwhil dividend remain unchang
acquisit strategi continu appear expens
final regard account practic remain
discourag high frequenc muddi segment
reclassif recent year
repres date owner name posit common share held report holder issuer
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
lift adjust ep outlook
previou forecast follow strong top-lin growth
second quarter anticip minor increas
fair valu estim updat assumpt
leav no-moat rate intact manag
rais adjust ep outlook
versu prior forecast mostli due broad end-
basi point compar year-ago
period mostli stem oper cost save
well benefit euroimmun
think diagnost segment growth
persist segment revenu grew organ versu
year-ago period driven double-digit growth genom
high-single-digit growth
reproduct health
segment perform quarter aid
compani chines blood-bank screen busi
infectious-diseas win tulip india addit
euroimmun experienc double-digit growth rel
year-ago period bolster part fda approv
sever assay expect food drug
administr approv euroimmun assay
continu boost near-term growth unit state
remain concern long-term potenti
also think custom uptak discoveri
analyt solut end market continu boost
segment da post organ revenu growth
versu year-ago period driven broad end-market
strength includ double-digit growth compani
life scienc busi notabl compani industri
food busi grew high singl digit versu
year-ago period agre manag
assert potenti trade tariff signific
issu compani expect compani
benefit emerging-market exposur
increas revenu adjust ep
outlook previou forecast follow strong top-
line growth first quarter anticip slight
increas fair valu estim updat
assumpt leav no-moat rate intact
higher organ revenu growth acquir
euroimmun asset foreign exchang benefit prompt
manag rais revenu outlook roughli
million billion versu prior billion
forecast adjust ep versu
prior forecast despit compani organ
revenu growth period adjust oper
margin fell basi point compar
euroimmun
oper expens surpris dynam
think higher cost perpetu
 activ constrain profit move forward
diagnost segment continu
benefit healthi growth opportun view
segment revenu grew organ quarter
driven euroimmun mid-teen organ revenu growth
rate expect fda approv euroimmun assay
bolster growth unit state ad benefit
reproduct health infecti diseas
oper emerg market howev still
skeptic compani long-term abil thwart
potenti peer segment competit intensifi
think increasingli cohes approach
discoveri analyt solut end market
continu benefit segment da post organ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
revenu growth period driven double-digit
growth compani informat onesourc
offer help off-set soft industri end
market furthermor think segment exposur
china continu support stabl growth rate
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
